A recent New Jersey federal court decision dealt a major blow to class action litigation that seek economic damages associated with the sale of products withdrawn from the market. 

In Gibriano v. Eisai, Inc., et al., 2024 WL 1831546 (D.N.J. Mar. 31, 2024), the plaintiff sought to represent a nationwide class of consumers who purchased a weight-loss medication that was recently voluntarily withdrawn from the market based on FDA’s concerns about potential cancer risk.  The plaintiff did not claim that she had suffered personal injuries.  Rather, she sought money damages, alleging that she over-paid because the medication “did not meaningfully impact her weight” and because the price she paid was “based on the understanding that it was safe.”  She further alleged that, because of the medication’s potential risks, “no reasonable physician would have prescribed [it] and no reasonable consumer would choose to purchase [it].”  In support of her allegations, the plaintiff attached to her complaint a consumer survey suggesting that knowledge of cancer risk would reduce the amount consumers would pay for a medication. 

The District of New Jersey dismissed the complaint for failure to plead a concrete and particularized injury-in-fact.  The court observed that the Third Circuit requires a plaintiff to allege that a product “failed to work for its intended purpose or was worth objectively less than what one could reasonably expect.”  The plaintiff’s “purely economic injur[ies,]” however, were “subjective” and “mere generalization.”  The attached survey did not save the plaintiff’s claims because the survey involved a generic, un-named weight-loss drug, and thus its relevance depended on “speculative inferences.”  Further, the plaintiff, “d[id] not state that she in fact suffered from a risk of cancer” because of taking the medication.  Rather, she sought reimbursement for a “functional product that she has already consumed without incident.”  The court squarely rejected the plaintiff’s price-premium theory of injury, reasoning that “Plaintiff’s assertion that she . . . would have paid less for an unsafe version of [the medication] does not state an injury-in-fact.”  Instead, the plaintiff needed to allege that the economic benefits she received were less than the price she paid.  Because she had not done so, the plaintiff failed to offer “a non-conjectural basis to show that she did not receive the benefit of her bargain,” and therefore she lacked Article III standing.   

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Andrew Soukup Andrew Soukup

Andrew Soukup serves as co-chair of the firm’s Class Action Litigation Practice Group. He specializes in representing heavily regulated businesses in class actions, multidistrict litigation, and other high-stakes disputes.

Praised for “big wins in his class action practice,” Andrew has defeated advertising, consumer…

Andrew Soukup serves as co-chair of the firm’s Class Action Litigation Practice Group. He specializes in representing heavily regulated businesses in class actions, multidistrict litigation, and other high-stakes disputes.

Praised for “big wins in his class action practice,” Andrew has defeated advertising, consumer protection, privacy, and product defect and safety claims with exposure ranging from millions to billions of dollars. His “proven record” has earned Andrew recognition as an “attorney you want on your side in a bet-the-company case.” Clients trust Andrew with their most important matters—whether he is leading a defense from the first filing or stepping in midstream with a fresh perspective.

Andrew represents clients in the consumer products, life sciences, financial services, technology, transportation, gaming, and media and communications industries. He has consistently prevailed in litigation in federal and state courts across the country against putative class representatives, government agencies, state attorneys general, and commercial entities.

Drawing on a long history of representing companies subject to extensive federal regulation and oversight, Andrew has a unique ability to help courts understand the complex environment that governs his clients’ businesses. He has earned praise for “understanding the big picture, the strategic vision of the individual case, and how that fits into the broader business strategy of the client.” Clients trust Andrew because of his successful outcomes at every stage of litigation, his responsiveness and attention to their matters, and his deep understanding of their businesses.

Andrew’s recent successes include:

Successfully defending several of the world’s leading companies and brands against class actions accusing them of engaging in deceptive marketing or selling defective products, including claims under state consumer protection and unfair and deceptive acts or practices statutes.
Defeating class certification in a privacy class action against one of the nation’s leading financial institutions.
Defeating industry-wide, multidistrict class-action claims against one of the nation’s leading consumer products companies challenging its marketing of over-the-counter medicine containing allegedly ineffective ingredients—a win that earned Andrew recognition by American Lawyer as a “Litigator of the Week.”
Delivering wins in multiple nationwide class actions for leading financial institutions over fees, disclosures, and other banking practices—including defending several institutions accused of violating the Paycheck Protection Program’s implementing laws, work that contributed to Covington’s recognition as a “Class Action Group of the Year.”
Representing multiple consumer product and life sciences companies against lawsuits seeking economic damages from the sale of products that allegedly caused personal injuries.
Defending several of the world’s most prominent companies against ESG-related claims accusing them of misrepresenting their practices.

Andrew has also achieved favorable outcomes navigating commercial and indemnification disputes between clients and their business partners involving contracts, fraud, and other business torts. He advises on arbitration agreements, has helped numerous clients avoid multidistrict and class-action litigation by enforcing them, and guides companies through mass arbitrations.

A recognized thought leader on class-action issues, Andrew regularly contributes to the firm’s blog, Inside Class Actions. He has been named a Lawyer of the Week by The American Lawyer, included on the Daily Journal’s list of Leading Commercial Litigators (2025), and ranked as a leading litigator by Chambers USA.

Watch: Andrew shares insights on class action litigation, as part of our Navigating Class Actions video series.